*
*
*
*
*
Top 
Course Schedule Programme
Monday, November 11th
8.00

Registration

 

9.00

Introduction to the Conference

Pier Franco Conte, Gabriel N. Hortobagyi

SESSION I - GENOMIC TOOLS FOR BREAST CANCER

 

9.15

Lecture 1: The new genomic landscape of breast cancer

Aleix Prat

9.45

Debate 1

Chairman: Massimo Rugge

Case 1: HR+early breast cancer. The question is: which tools can be used to predict efficacy of adjuvant chemotherapy in addition to endocrine therapy

Presenter: Cristina Falci
Discussants:
- for GEPs - Giampaolo Bianchini
- for IHC and clinico-pathological tools - Anna Sapino

11.15

Coffee break

 

11.30

Lecture 2: Predicting the efficacy of anticancer drugs

Gabriel N. Hortobagyi

SESSION II - MANAGEMENT OF FAMILIAL CANCER SYNDROMES

 

12.00

Round Table 1: A young patient with triple negative early breast cancer will be presented by a young oncologist to address the following questions

1. When to test for BRCA or other genetic syndromes
2. Locoregional management of BRCA mutated tumors
3.Medical adjuvant treatment for BRCA mutated tumors
4.Surveillance of patients with BRCA mutated tumors
Presenter: Zora Baretta

Round table discussion

Chairman: Pier Franco Conte
Panelists: Fernando Bozza, Emma D’Andrea, Giorgio De Santis, Gabriel N. Hortobagyi, Sibylle Loibl, Marco Montagna, Philip Poortmans, Tania Saibene, Stefania Zovato

13.00

Lunch

 

SESSION III - LOCOREGIONAL TREATMENT

 

14.00

Debate 2

Chairman: Pier Franco Conte

Case 1: a case of cT1cN0 BC candidate for breast conserving surgery with a positive SNB to be presented by a young doctor. Question: can AND be spared?

Presenter: Tania Saibene
Discussants:
- Yes: Monica Morrow
- No: Alberto Costa

14.45

Case 2: a case of early breast cancer pt candidate for NACT: SNB or not? If yes, when?

Presenter: Silvia Michieletto
Discussants:
- Before: Eleftherios Mamounas
- After: Thorsten Kuhn

15.30

Round Table 2: Locoregional treatments in a patient achieving a good response after NACT

Presenter: Enrica Baldan

Round table discussion

Chairman: Gabriel N. Hortobagyi
Panelists: Fernando Bozza, Alberto Costa, Giorgio De Santis, Thorsten Kuhn, Eleftherios Mamounas, Silvia Michieletto, Monica Morrow, Enrico Orvieto, Luigi Pescarini, Philip Poortmans

16.15

Coffee break

 

16.30

Lecture 3: Ongoing trials on partial breast irradiation

Filippo Bertoni

17.00

Discussion

 

17.30

Adjourn

 

Tuesday, November 12th
9.00

Lecture 4: Management of uncommon histologies

Valentina Guarneri

SESSION IV - METASTATIC BREAST CANCER

 

9.30

Lecture 5: New algorithms for the treatment of HR+MBC

Stephen Johnston

10.00

Lecture 6: New algorithms for the treatment of HER2+MBC

Sibylle Loibl

10.30

Lecture 7: Standard of care and promising new agents for TN MBC

Jonas Bergh

11.00

Coffee break

 

11.30

Lecture 8: Modulation of metastatic breast cancer biology by treatment outcomes

Christoph Zielinski

12.00

Discussion

 

12.30

Lunch

 

Clinical case discussion

 

13.45

Case 1: a case of de novo MBC. Question: surgery of primary tumor?

Presenter: Cristina Falci

14.15

Case 2: management of brain recurrence without other metastatic sites

Clinical case: TNBC
Clinical Case: HER2+
Presenter: Maria Vittoria Dieci

14.45

Case 3: management of brain progression in patient with extra-CNS disease

Presenter: Antonella Brunello

Panel discussion

Fernando Bozza, Pier Franco Conte, Shaheenah Dawood, Gabriel N. Hortobagyi, Jacek Jassem, Donato Nitti, Philip Poortmans, Guido Sotti

15.15

Lecture 9: Management of lepto-meningeal metastasis

Shaheenah Dawood

15.45

Coffee break

 

16.15

Ceremony for the presentation of the Award for Advances in Breast Cancer Research and the Monica Boscolo Research Grant

 

17.00

Lecture of the Awardee

 

17.30

Adjourn

 

Wednesday, November 13th

SESSION V - HIGHLIGHTS FROM SABCS/ASCO/ECCO

 

9.00

Highlights from biology

Grazia Arpino

9.20

Early breast cancer

Paolo Pronzato

9.40

Advanced breast cancer

Stefania Gori

10.00

Lecture 10: Role of locoregional treatments for metastatic breast cancer

Miguel Martín

10.30

Coffee break

 

11.00

Lecture 11: Targeted agents in the neoadjuvant treatment

Fikri Içli

11.30

Lecture 12: Primary chemotherapy as a surrogate endpoint for accelerated drug approval: opportunities and limitations

David Khayat

12.00

Lecture 13: New actionable pathways in breast cancer subtypes

Ana Maria Gonzalez-Angulo

12.30

Adjourn and final evaluation questionnaire

 

Top 
Directors And Other Speakers
Speaker 1

Pier Franco Conte

Division of Medical Oncology 2

Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Scientific Committee

Alberto Amadori

Division of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Ermanno Ancona

Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jonas Bergh

Department of Oncology-Pathology
Karolinska Institute and University Hospital
Stockholm (SW)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Fikri Içli

Oncology Research and Treatment Center
Ankara University (TR)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Speakers

Grazia Arpino

Department of Endocrinology and Molecular and Clinical Oncology
University Federico II
Naples (I)

Enrica Baldan

Breast Unit
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Zora Baretta

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Jonas Bergh

Department of Oncology-Pathology
Karolinska Institute and University Hospital
Stockolm (SW)

Filippo Bertoni

Department of Oncology and Haematology and Respiratory Diseases
University Hospital of Modena (I)

Giampaolo Bianchini

Department of Medical Oncology
IRCCS San Raffaele Hospital
Milan (I)

Fernando Bozza

Division of Breast Surgery
Istituto Oncologico Veneto IRCCS
Padua (I)

Antonella Brunello

Division of Medical Oncology 1
Istituto Oncologico Veneto IRCCS
Padua (I)

Alberto Costa

European School of Oncology
Milan (I)

Emma D’Andrea

Hreditary Tumors Group Breast and Ovary Cancer
Department of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Shaheena Dawood

Department of Medical Oncology
Dubai Hospital
United Arab Emirates

Giorgio De Santis

Department of Plastic, Recontructive and Aesthetic Surgery
University Hospital of Modena (I)

Maria Vittoria Dieci

Department of Oncology, Hematology and Respiratory Diseases
University Hospital
University of Modena and Reggio Emilia (I)

Cristina Falci

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Ana Maria Gonzalez-Angulo

Md Anderson Cancer Center
Breast Medical Oncology
Houston, TX (USA)

Stefania Gori

Department of Medical Oncology
Santa Maria della Misericordia Hospital
Perugia (I)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Fikri Içli

Oncology Research and Treatment Center
Ankara University (TR)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Picture

Gabriel N. Hortobagyi

Department of Breast Medical Oncology

University of Texas - MD Anderson Cancer Center
Houston (USA)

 

David Khayat

Medical Oncology Department
Pitié-Salpétrière Hospital
Paris (F)

Sibylle Loibl

German Breast Group
Department of Medicine and Reasearch
University of Frankfurt (D)

Miguel Martín

Medical Oncology Service
Hospital Universitario Gregorio Maranon
Madrid (S)

Donato Nitti

Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Philip Poortmans

Department of Radiation Oncology
Dr. Verbeeten Instituut
Tilburg (NL)

Christoph Zielinski

Clinical Division of Oncology
Medical University - General Hospital
Wien (A)

 

David Khayat

Medical Oncology Department
Pitié-Salpétrière Hospital
Paris (F)

Thorsten Kuhn

Department of Ginecology and Obstetrics
Klinikum Esslinger
Esslingen (D)

Sibylle Loibl

German Breast Group
Department of Medicine and Reasearch
University of Frankfurt (D)

Eleftherios Mamounas

Altman Health Foundation
Brest Cancer Unit
Canton – Ohio (USA)

Miguel Martín

Medical Oncology Service
Hospital Universitario Gregorio Maranon
Madrid (E)

Silvia Michieletto

Division of Breast Surgery
Istituto Oncologico Veneto IRCCS
Padua (I)

Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer
Department of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Monica Morrow

Breast Service, Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York (USA)

Donato Nitti

Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Enrico Orvieto

General Pathology & Cytopathology Unit
Department of Medicine-DIMED
University of Padua (I)

Luigi Pescarini

Breast Unit
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Philip Poortmans

Department of Radiation Oncology
Dr. Verbeeten Instituut
Tilburg (NL)

Aleix Prat

Institute of Oncology (VHIO)
Vall d’Hebron
Barcellona (E)

Paolo Pronzato

Department of Medical Oncology
National Cancer Institute
Genoa (I)

Massimo Rugge

General Pathology & Cytopathology Unit
Department of Medicine-DIMED
University of Padua (I)

Tania Saibene

Division of Breast Surgery
Istituto Oncologico Veneto IRCCS
Padua (I)

Anna Sapino

Department of Biomedical Science and Human Oncology
University of Torino (I)

Guido Sotti

Department of Radiotion Oncology
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Cristoph Zielinski

Clinical Division of Oncology
Medical University Vienna - General Hospital
Wien (A)

Stefania Zovato

Unit of Endocrinology Oncology
Istituto Oncologico Veneto IRCCS
Padua (I)

Top 

Advanced International Breast Cancer Course

Breast cancer is the first lethal, common, and chronic disease where treatment can significantly reduce mortality. This success is the result of impressive advances in the knowledge of breast cancer biology, molecular characterization of the disease, screening programs, advanced imaging, multimodal local therapies and molecularly targeted drugs.

Nowadays, breast cancer represents the frontrunner in the path from comparative effectiveness where new therapeutic interventions are implemented on the basis of  “average” benefit to personalized cancer medicine where the right treatment is provided to the right patient at the right moment. An updated, multifaceted approach to our patients is now becoming more and more demanding and with these goals in mind, the Programme of this international Conference includes lectures on the molecular characterization of primary and metastatic tumors, update management of early and advanced disease, strategies to overcome resistance to available therapies, innovative therapies, and multimodal treatments for advanced disease. Clinical case discussions and debates are also planned to discuss topics which require a multifaceted approach or are matter of controversy.

This 9th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 9th AIBCC will award the 4th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year and the Monica Boscolo Research Grant to an Italian scientist for a research project to be conducted in cooperation with a foreign institution.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

The Conference will include:

  1. Lectures:
    Internationally recognized speakers provide a balanced overview of selected topics
  2. Round Tables:
    Panelists debate items which require a multi-faceted approach
  3. Clinical Case Discussions:
    Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced breast cancer will be presented. All participants will be requested to express their vote among a predefined list of options.
    Expert panelists will then provide their opinion and discuss the audience choices.
  4. Highlights:
    Internationally recognized speakers give an update of significant advances presented at major meetings (ASCO, ESMO, SABCS) on preselected topics
  5. Debates:
    A speaker will illustrate a clinical case where the use of a specific technique, diagnostic tool or treatment might change patient management.
    Two experts will take a different view on the clinical utility of this approach.

Addressed to

Oncologists, radiologists, radiation oncologists, pathologists, surgeons


Official Language

The official language of the meeting is English. No simultaneous translation will be provided.

Top 
How to Attend General Information

Meeting venue:

Centro Congressi Padova A. Luciani
via Forcellini 170/a, Padova

How to reach the meeting venue